首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): A single-institution study of 224 Japanese AML patients.
【24h】

Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): A single-institution study of 224 Japanese AML patients.

机译:从头进行的急性髓细胞性白血病(AML)中CBFB / MYH11融合基因的检测:一项针对224名日本AML患者的单机构研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The cytogenetic findings in acute myeloid leukemia (AML) are a powerful prognostic indicator. Among these abnormalities, the World Health Organization has classified inv(16)(p13q22), which is closely associated with the M4E classification in the French-American-British system, as indicating a good-risk AML. However, this chromosomal abnormality can often be difficult to detect. In this study, we used RT-PCR and FISH analysis to examine 224 Japanese adult de novo AML patients for the presence of the CBFB/MYH11 fusion transcript at the time of diagnosis. The CBFB/MYH11 fusion gene was detected in 17 patients (7.6%): eight patients had the inv(16) chromosome and in all of them it was M4E; nine patients did not have abnormalities in chromosome 16. AML with the CBFB/MYH11 fusion gene but without inv(16) was found in M2, M4, and M5, but not in M4E patients. There were no statistically significant differences in the clinical features of patients with the inv(16) and those with the cryptic inv(16) chromosome. These results indicate that even if eosinophilia is not found, molecular screening for CBFB/MYH11 fusion gene should be performed in all AML patients at the time of diagnosis to help guide disease management.
机译:急性髓细胞性白血病(AML)的细胞遗传学发现是有力的预后指标。在这些异常中,世界卫生组织已将inv(16)(p13q22)分类为高风险AML,该inv(16)(p13q22)与法裔美英系统中的M4E分类密切相关。但是,这种染色体异常通常难以检测。在这项研究中,我们使用RT-PCR和FISH分析在诊断时检查了224名日本成年新发AML患者中CBFB / MYH11融合转录本的存在。在17例患者(7.6%)中检测到CBFB / MYH11融合基因:8例患者具有inv(16)染色体,所有患者均为M4E。 9名患者的16号染色体没有异常。在M2,M4和M5中发现具有CBFB / MYH11融合基因但没有inv(16)的AML,但在M4E患者中未发现异常。 inv(16)染色体患者和隐性inv(16)染色体患者的临床特征无统计学差异。这些结果表明,即使未发现嗜酸性粒细胞增多,也应在诊断时对所有AML患者进行CBFB / MYH11融合基因的分子筛查,以帮助指导疾病管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号